Cibus Inc. Files Initial Statement of Beneficial Ownership for Director Craig Wichner

Cibus Inc. has filed an initial statement of beneficial ownership with the SEC, listing Craig Wichner as a director. This filing is accessible via EDGAR, the SEC's system. The news brief was generated by Public Technologies using AI and is for informational purposes only.

Cibus, Inc. Earnings Call Highlights Progress and Challenges

Cibus, Inc.'s Q3 earnings call highlighted progress in commercialization, particularly in rice herbicide tolerance traits and biofragrance products. The company faces challenges, including revenue decline and cash runway concerns. Notable achievements include signing customer agreements in the USA and Latin America, successful biofragrance scale-up, and regulatory advancements. However, regulatory delays in the EU and financial performance issues persist. Cibus aims to reduce operational costs and projects significant potential royalties from its products, with commercial launches planned for Latin America, the U.S., and Asia in the coming years.

Cibus’s Strategic Initiatives and Financial Improvements Drive Buy Rating

Wall Street analyst Amit Dayal from H.C. Wainwright maintained a Buy rating on Cibus with a $25.00 price target. The rating is based on Cibus's strategic initiatives, financial improvements, commercialization of biofragrance products, cost-cutting measures, optimization of gene editing processes, and international expansion efforts. Favorable regulatory developments in the UK and EU and potential catalysts like new partnerships support the positive outlook.

Cibus | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 615 K

Gene editing firm Cibus misses Q3 revenue estimates

Cibus reported Q3 revenue of $615,000, missing the $1.39 million estimate, with a net loss of $24.3 million. The company plans strategic partnerships and cost reductions for growth, targeting rice trait launches in Latin America by 2027 and expanding its Sustainable Ingredients program by 2026. Analysts rate Cibus shares as "buy," with a median price target of $15.50, significantly above the current price.